☰
Supply Chain Ecosystem Analysis now part of DBMR Reports
Global Non-Cardioselective Beta Blockers Market, By Indication (Angina, Hypertension, Heart Failure, Arrhythmias, Others), Target (Beta-1 Receptors, Beta-2 Receptors, Others), Drugs (Propranolol, Nadolol, Labetalol, Carvedilol, Sotalol, Timolol, Pindolol, Others), Route of Administration (Oral, parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
The global non-cardioselective beta blockers market is expected to witness huge growth in the forecast period. Rising cases of hypertension and other cardiovascular diseases boosts the non-cardioselective beta blockers market. It is used to prevent, or improve symptoms in people who've abnormal coronary heart rhythm, Chest ache, coronary heart assaults, coronary heart failure, Migraine, kinds of tremors. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global non-cardioselective beta blockers market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Non-cardioselective beta blockers are the type of agents that are used in a wide variety of cardiovascular diseases including heart failure, angina, hypertension and other cardiovascular diseases. They do not precisely target the beta 1 receptor, rather they target both the beta-1 as well as beta-2 receptors. These agents cause major bronchial constriction and could be harmful especially in patients with respiratory conditions such as asthma or chronic obstructive pulmonary disease.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Angina, Hypertension, Heart Failure, Arrhythmias, Others), Target (Beta-1 Receptors, Beta-2 Receptors, Others), Drugs (Propranolol, Nadolol, Labetalol, Carvedilol, Sotalol, Timolol, Pindolol, Others), Route of Administration (Oral, parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Zydus Cadila (India), Pfizer Inc (U.S.), Lupin (India), GSK Plc (U.K.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals (U.S.), Pierre Fabre Group (France)
|
|
Market Opportunities
|
|
Drivers
According to the WHO, around 60% - 85% of population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 U.S. adults meets the appropriate need of physical activity. This boost the market growth.
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
Rising awareness about the beta blockers and studies that are conducted for development in identifying the diseases that by government and private companies for better knowledge of these blockers is likely to drive the market growth.
The rise in the number of calcium channel blockers delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
The lack of qualified personnel who are unable to treat the patients with these agents could curb the growth of the global non-cardioselective beta blockers market over a forecast period.
The huge expenditure associated with these agents surely hamper the market growth.
This global non-cardioselective beta blockers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global non-cardioselective beta blockers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The COVID-19 pandemic faced moderately great impact on the market growth. Hypertension is one of the most common phenomenon in COVID-19 patients; thus, beta-blockers are widely used. In addition to this, the pandemic is interrupting the medical supply chain, and the delivery of the prooducts. But in the post pandemic era, the market is rising as the hospitals and clinics are free from the tedious responsibilities of COVID-19 patients.Thus, the market will undergo growth during the forecast period..
The global non-cardioselective beta blockers market is segmented on the basis of indication, drugs, target, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
Target
Drugs
Route of Administration
End User
Distribution Channel
The global non-cardioselective beta blockers market is analysed and market size insights and trends are provided by indication, drugs, target, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global non-cardioselective beta blockers market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global non-cardioselective beta blockers market throughout the forecasted period due to the presence of key manufacture of the product, high research and development and healthcare expenditure and skilled professionals.
Asia-Pacific dominates the market due to increased government awareness programs, increased population, and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The global non-cardioselective beta blockers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global non-cardioselective beta blockers market
Key players operating in the global non-cardioselective beta blockers market include:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
